Last Update 05 May 26
TRAK: Expanding Food Traceability Adoption And Compliance Wins Will Drive Upside
Analysts have kept their ReposiTrak price target effectively unchanged at approximately $16.00, reflecting only very small tweaks in inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the stock.
What's in the News
- A wholesale grocery cooperative in the Southern United States became the first wholesaler to reach full supplier to store traceability using ReposiTrak’s Touchless Traceability solution, achieving FSMA 204 compliance without case-level scanning or changes to distribution center workflows (Key Developments).
- Erewhon, a California-based specialty grocery retailer, selected ReposiTrak’s cloud-based Compliance Management solution to centralize supplier documentation, manage regulatory requirements including FSMA 204, and monitor supplier compliance in real time as it grows its supplier network (Key Developments).
- Eighteen fresh fruit and vegetable companies across categories such as leafy greens, citrus, apples, berries, tomatoes, avocados and fresh-cut produce joined the queue for the ReposiTrak Traceability Network to share FDA-required Key Data Elements for food traceability with their retail, wholesale and foodservice customers (Key Developments).
- ReposiTrak and SPAR Group, Inc. entered into an agreement that combines ReposiTrak’s technology for scan-based trading, inventory accuracy and out-of-stock detection with SPAR’s nationwide service workforce. The agreement is aimed at improving on-shelf availability and reducing store labor strain through on-demand merchandising support (Key Developments).
- From October 1, 2025 to December 31, 2025, ReposiTrak repurchased 79,927 shares for US$1.1 million, bringing total repurchases under the program announced on May 9, 2019 to 2,220,026 shares, or 11.63%, for US$14.46 million (Key Developments).
Valuation Changes
- Fair Value: Held steady at about $16.00 per share, with no meaningful change in the updated model.
- Discount Rate: Adjusted slightly from 8.460421% to 8.455293%, reflecting a very small refinement in the risk assumption.
- Revenue Growth: Kept effectively unchanged at 6.718914%, with the updated figure matching the prior estimate.
- Net Profit Margin: Maintained at roughly 33.37%, with the revised estimate at 33.372231%.
- Future P/E: Tweaked marginally from 36.41x to 36.40x, leaving the long-term earnings multiple assumption largely intact.
Key Takeaways
- Strategic focus on automation and partnerships enhances scalability, market reach, and incremental profitability, improving margins by reducing costs.
- Anticipated double-digit growth, driven by traceability demand and strategic initiatives, signals substantial earnings improvement and increased shareholder value.
- Uncertainty in FDA laws, rising expenses, and intense competition may hinder ReposiTrak's revenue growth and strategic investment potential.
Catalysts
About ReposiTrak- A software-as-a-service provider, designs, develops, and markets proprietary software products in North America.
- ReposiTrak is poised to benefit from the accelerating need for end-to-end traceability in the grocery industry, driven by both regulatory mandates and market forces, which is expected to significantly increase top-line revenue.
- The company’s deferred revenue growth of 70% indicates a strong increase in future subscription revenue, expected to contribute an additional $1.7 million incrementally over the next 12 months, significantly improving earnings and profitability.
- The strategic focus on automation and onboarding via the Wizard platform improves scalability and customer acquisition efficiency, potentially increasing margins by reducing human interaction costs and boosting incremental profitability.
- ReposiTrak’s position as the largest operational traceability network attracts partnerships with key industry players like Upshop, expanding market reach and potentially driving additional revenue streams.
- Anticipated double-digit revenue growth in the second half of the fiscal year, with a target of 10% to 20% annual growth, indicates substantial upcoming improvements in earnings and shareholder value.
ReposiTrak Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming ReposiTrak's revenue will grow by 6.7% annually over the next 3 years.
- Analysts assume that profit margins will increase from 29.8% today to 33.4% in 3 years time.
- Analysts expect earnings to reach $9.5 million (and earnings per share of $0.45) by about May 2029, up from $7.0 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 38.5x on those 2029 earnings, up from 25.9x today. This future PE is greater than the current PE for the US Software industry at 31.6x.
- Analysts expect the number of shares outstanding to decline by 0.4% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.46%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The uncertainty surrounding the FDA's enforcement of traceability laws could delay the adoption of ReposiTrak's services, impacting future revenue growth.
- An increase in operating expenses, such as sales and marketing expenses and employee benefit costs, may squeeze net margins if not managed alongside revenue growth.
- The growth in cash reserves is commendable, but a focus on preferred share redemption and dividends might limit the funds available for strategic investments, potentially affecting long-term earnings growth.
- Intensive competition from large retailers managing traceability internally or through other partnerships could limit ReposiTrak's market share and negatively affect revenue.
- Heavy reliance on technology investments like the Wizard platform for onboarding could pose risks if implementation delays occur, potentially impacting revenue recognition and cash flow projections.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $16.0 for ReposiTrak based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $28.6 million, earnings will come to $9.5 million, and it would be trading on a PE ratio of 38.5x, assuming you use a discount rate of 8.5%.
- Given the current share price of $9.97, the analyst price target of $16.0 is 37.7% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on ReposiTrak?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.